Clene Nanomedicine, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2013-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.clene.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Intermediate Expanded Access Protocol CNMAu8.EAP04
- Conditions
- ALSAmyotrophic Lateral SclerosisPALS
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Clene Nanomedicine
- Registration Number
- NCT06408727
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸Columbia Unniversity, New York, New York, United States
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: CNMAu8
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 40
- Registration Number
- NCT05299658
- Locations
- 🇦🇺
Concord Hospital, Concord, New South Wales, Australia
🇦🇺Neuroscience Research Australia, Randwick, New South Wales, Australia
Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS
- Conditions
- Amyotrophic Lateral Sclerosis
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Clene Nanomedicine
- Registration Number
- NCT05281484
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸UC Irvine, Orange, California, United States
🇺🇸Sutter Health (Enrollment is full, not recruiting), San Francisco, California, United States
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 55
- Registration Number
- NCT04626921
- Locations
- 🇦🇺
Sydney Brain Mind Centre, Camperdown, New South Wales, Australia
🇦🇺John Hunter Hospital, New Lambton Heights, New South Wales, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Clene Nanomedicine
- Target Recruit Count
- 296
- Registration Number
- NCT04610138
- Locations
- 🇧🇷
PROCAPE, Santo Amaro, Recife, Brazil
🇧🇷Projeto Praca Onze, Centro, Rio De Janeiro, Brazil
🇧🇷IBPClin, Gloria, Rio De Janeiro, Brazil
- Prev
- 1
- 2
- 3
- Next
News
HEALEY ALS Platform Trial: Streamlining Drug Development for Amyotrophic Lateral Sclerosis
The HEALEY ALS Platform Trial is pioneering a new approach to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS).
Multiple Sclerosis Pipeline Shows Promise with Novel Therapies in Development
• The multiple sclerosis (MS) therapeutic landscape is expanding, with over 80 active pipeline therapies currently in development by more than 75 companies. • Recent clinical trials have yielded mixed results, with some therapies showing promise in specific MS subtypes, such as non-relapsing secondary progressive MS (nrSPMS). • Regulatory milestones have been achieved, including FDA approval for new formulations and fast-track designations for therapies targeting progressive MS. • Emerging therapies in the MS pipeline include monoclonal antibodies, oral treatments, and CAR-T cell therapies, offering diverse mechanisms of action and routes of administration.